ABSTRACT Anxiety disorders are among the most prevalent mental disorders in the general population. Nearly 30 million persons are affected in the United States, with women affected nearly twice as frequently as men. These disorders are frequently treated using benzodiazepines (Diazepam) and non-benzodiazepines (Zaleplon). Non-benzodiazepines have replaced the benzodiazepines for anxiety treatment due to low risk of dependence and CNS effects encouraging drug abuse.
quality of sleep or early awakening with inability to fall asleep again (Sylvers et al., 2011) .
Anxiety disorders are among the most prevalent mental disorders in the general population. Nearly 30 million persons are affected in the United States, with women affected nearly twice as frequently as men. These disorders are associated with significant morbidity and often are chronic and resistant to treatment (Curran and Chalasani, 2012) and they can be viewed as a family of related but distinct mental disorders, which include the following: panic disorder with or without agoraphobia, agoraphobia with or without panic disorder, specific phobia, social phobia, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), acute stress disorder and generalized anxiety disorder (Doyle and Pollack, 2003; Pigott, 2003; Henig, 2009) .
Sleep disorders are frequently treated using benzodiazepine (ex. Diazepam) and non-benzodiazepine (ex. Zaleplon) anxiolytics (Morin et al., 2004; Dolder et al., 2007) . Where, anxiolytics should be prescribed for short periods only with the frequency and duration of use customized to each patient's circumstances (Ramakrishnan and Scheid, 2007) .
Benzodiazepine anxiolytics are most useful for short term treatment in promoting sleep. However, long term use may lead to adverse effects and withdrawal phenomena, such as; sleepiness and reduced alertness (Becker, 2006; Naghibi and Rayatnia, 2011) . In contrast, the newer generation non-benzodiazepine anxiolytics have no significant adverse effects and withdrawal phenomena when taken as recommended, making them the best first line choice for long term treatment of anxiety (Follesa et al., 2002; PandiPerumal et al., 2006) . Also, the nonbenzodiazepines have largely replaced the benzodiazepines for anxiety treatment due to low risk of tolerance, dependence and residual central nervous system effects compared with benzodiazepine anxiolytics (Noguchi et al., 2002; Ganzberg et al., 2005; Foda and Bakhaidar, 2010) . So, these benefits of non-benzodiazepine anxiolytics encourage the patients to take overdose of this type of anxiolytics leading to drug abuse.
The aim of this work was to investigate the toxicological overdose effect of some anxiolytic drugs (ex. Zaleplon and Diazepam) on behavior, blood pressure, heart rate, brain neurotransmitter content and liver & kidney functions in experimental animals by using several parameters as well as to study the probable mechanism(s) of action of these anxiolytic drugs.
MATERIALS AND METHODS Animals
Male Sprague Dawley rats (120 -130 gm) were purchased from the animal house of National research center (Dokki, Giza, Egypt). Animals were acclimatized in the animal house of pharmacology department -National research center of Egypt, for at least one week prior to experimentation. Animals were kept at 22 ± 3°c and 5% relative humidity during the whole experiment. Standard food pellets and water were supplied. Animals' treatment protocol was approved by National Research Center Animal Right Committee.
Drugs
In the current study, diazepam and zaleplon were used and obtained from Egyptian International Pharmaceutical Industries Co. (EIPICO), Egypt, and Sigma company, Egypt, respectively. These drugs were suspended in sterile bidistilled water using 1% tween 80 immediately before administration.
Experimental design
Animals (Adult male Sprague Dawley rats) were randomly divided into five groups; each consists of ten animals according to the following scheme: Group (1) 
Biochemical measurement
Blood samples were obtained from retro-orbital plexus of veins of each animal under light anaesthesia by diethyl ether, 24 hours after last treatment, and collected in non-heparinized tubes. The non-heparinized blood was allowed to coagulate and then centrifuged to separate the serum. Serum was obtained by blood centrifugation at 2500 rpm for 10 minutes, liquated and stored at -20°C for biochemical analysis (Cocchetto and Bjornsson, 1983) .
METHODS
The present study was done by the following: a) Behavioral study including assessment of motor co-ordination by using the rotarod test (Kauppila et al., 1991; Lundblad et al., 2003) and anxiety performance by using the elevated plus maze test (Salum et al., 2003; Braun et al., 2011) . b) Measurement of blood pressure and heart rate by using tail-cuff technique (Irvine et al., 1997) . c) Determination of the free amino acid and monoamine contents in the whole brain by using HPLC (Heinrikson and Meredith, 1984; Pagel et al., 2000) . d) Determination of serum aminotransferases activity (Reitman and Frankel, 1957) , total protein (Henry et al., 1974) , total & direct billirubin (Walter and Stucki, 1970) , creatinine (Degiorgio, 1974 ) and blood urea nitrogen (Tabacco et al., 1979) .
Statistical analysis
Data were presented as mean ± Standard error. Comparisons between means were carried out using two way ANOVA test. When a significant F value was obtained, Bonferroni post hoc analysis was performed to determine specific differences.
A probability level of less than 0.05 was accepted as being significant in all types of statistical tests. SPSS software program (version 14) was used to carry out all statistical tests. 
RESULTS

Behavioral
Biochemical measurement
Effect of diazepam and zaleplon on rats' serum total protein
Diazepam (1 and 4 mg/kg, p.o.) and zaleplon (4 mg/kg, p.o.) caused significant decrease on serum total protein by 8.3%, 10.5% and 6.3% after four weeks respectively comparing to corresponding control group values as shown in Figure (9) . Effect of diazepam and zaleplon on rats' serum direct billirubin Diazepam (4 mg/kg, p.o.) showed significant increase on serum direct billirubin by 25% after two weeks and Effect of diazepam and zaleplon on rats' serum total billirubin Diazepam (1 mg/kg, p.o.) and zaleplon (4 mg/kg, p.o.) induced significant increase on serum total billirubin by 13.9% and 20% respectively after four weeks. Also, diazepam (4 mg/kg, p.o.) led to significant increase on serum total billirubin by 11.1% after two weeks and 30.4% after four weeks in comparison with that of corresponding control group values as shown in Figure ( For the motor co-ordination assay, the results of the current work for zaleplon (1 and 4 mg/kg, p.o.) were supported by Sanger et al., (1996) , who reported that; in general, zaleplon had no effect on rotarod performance when taken as recommended dose (1 mg/kg) for short term of administration (15 days). However, it obtained a decrease in rotarod performance (muscle incoordinaion) incase of high dose (3 mg/kg) for long term of administration (30 days). In addition, Foster et al., (2004) reported that; zaleplon affected on rotarod performance in a dosedependant manner. So, high dose of zaleplon administration (5 mg/kg) produced rotarod performance deficits, which attributed to muscle relaxation.
Also, the results of the present work for diazepam (1 & 4 mg/kg, p.o.) were in agreement with Sarris (2007); Bodkin et al., (2012), who reported that, diazepam had no effect on performance of rats on the rotarod for short term of administration. However, for long term of diazepam administration, there was a clear effect on performance of rats on the rotarod by decreasing the ability of rats to balance on the rotarod, deducing that: diazepam may exert its anxiolytic action by direct action on the central nervous system giving muscle relaxation and not through sedation.
For the anxiety performance assay, the results of the present study for zaleplon ( Himmel (2008) reported that; diazepam resulted in CNS depression and decrease in anxiety performance, where it acts as a positive allosteric agonist of the postand pre-synaptic GABA A receptorchloride channel complex leading to potentiating the activity of brain's major inhibitory neurotransmitter (GABA) and lowering the activity of brain's major excitatory neurotransmitters (Glutamate and Aspartate) of rats.
As regard for the heart rate and blood pressure measurement, the results of the present work for zaleplon (1 and 4 mg/kg, p.o.) were explained by Mandrioli et al., (2010) , who reported that; zaleplon has no effect on blood pressure or heart rate at recommended doses (1 mg/kg). However at high doses (3 and 5 mg/kg) especially with long term of administration (one month), it decreased significantly the heart rate and blood pressure, where the adverse effects associated with zaleplon seem to be more rapidly resolved and less severe than those associated with benzodiazepine and other non-benzodiazepine hypnotics with a longer duration of action. Also, Weitzel et al., (2000) reported that; zaleplon decreased heart rate and blood pressure at high dose only (4 mg/kg) with a lesser extent than benzodiazepine hypnotics. But at therapeutic dose (1 mg/kg), there is no effect on heart rate or blood pressure. Moreover, Sanchez et al., (2000) stated that; zaleplon has no effect on blood pressure or heart rate, when administered at recommended dose (1 mg/kg) either alone or in combination with digoxin.
Also, the results of the current study for diazepam ( 
, who reported that; systolic and mean blood pressure and heart rate decreased significantly after diazepam administration (1 mg/kg) attributing to central action of diazepam not peripheral one. Where, the nucleus of the solitary tract in the medulla plays an important role in controlling blood pressure and contains GABA receptors. Also, hypothalamus plays an important role in controlling blood pressure. As, diazepam acted directly on GABA receptors in medulla as an agonist and on hypothalamus.
As regard for brain neurotransmitters (Free amino acids and where it acts as a positive allosteric agonistic of the post-and pre-synaptic GABA A receptor -chloride channel complex leading to potentiating the activity of brain's major inhibitory neurotransmitter (GABA) and lowering the activity of brain's major excitatory neurotransmitters (glutamate and aspartate). Which explain our present result for GABA, glutamate and aspartate. Furthermore, the increase in brain dopamine and serotonin levels in current result is clarified by Straub et al., (2010) who reported that, diazepam elevated dopamine and serotonin content in the brain of mice due to its dopaminergic and serotonergic activity. Oppositely, it lowered nor-epinephrine content in the brain of mice resulting in calming down and anxiolytic effect.
As regard for the hepatotoxiciy assay, the results of the present work for zaleplon ( As regard for the nephrotoxicity assay, the results of the present work for zaleplon (1 and 4 mg/kg, p.o.) were in line with Moore et al., (2003) , who reported that; zaleplon is used widely as an anxiolytic drug due to its high safety margin on vital organs, but its long term use (6 weeks) especially with high dose (4 mg/kg) for treatment of anxiety and insomnia induced mild nephrotoxicity, where serum creatinine and urea nitrogen were elevated but urea nitrogen elevation was with a lesser extent than serum creatinine elevation. Also, Petroski et al., (2006) 
